Literatura
Literatura:
[1] FUNFACK, Volf. Introductory Seminar about metabolic balance® : English Version. In Einfúrhrungsseminar. Isen : [s.n.], August 31, 2010 . s. 37.
[2] Djousse, L. et al.; Egg consumption in relation to cardiovascular disease and mortality: the story gets more complex at: www.ajcn.org/cgi/reprint/87/4/964
[3]Volek, J.S. et al.; Carbohydrate Restriction has a More Favorable Impact on the Metabolic Syndrome than a Low Fat Diet at: www.springerlink.com/content/v57212m331741w24
[4] Forouhi, N.G et al.; Dietary fat intake and subsequent weight change in adults: results from the European Prospective Investigation into Cancer and Nutrition cohorts at: www.ajcn.org/cgi/reprint/92/2/463
[5] Skeaff Fats and Fatty Acids in Human Nutrition Joint FAO/WHO Expert Consultation, Geneva, November 2008. At: content.karger.com/ProdukteDB/produkte.asp?Aktion=showproducts&searchWhat=books&ProduktNr=251867
[6] Mozaffarian “Effects on coronary heart disease, a meta-analysis of randomized controlled trials. At: www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000252#abstract2
[7] EVA LOPATOVÁ; ŠKOLITEL: RNDR. OMAR ŠERÝ, PH.D.; Cholesterol. 2006-Brno. URL < http://is.muni.cz/th/77989/prif_b/Bakalarska_prace.txt >
[8] SKOUMALOVÁ ALICE. Cholesterol a jeho transport. URL < www.lf2.cuni.cz/Ustavy/biochemie/vyuka/cholesterol.ppt >.
[9] MGR. EDUARD JIRKOVSKÝ MGR. LEOŠ FUKSA, MGR. EVA BRČÁKOVÁ. HYPOLIPIDEMIKA. 2009. LF2. URL < www.lfhk.cuni.cz/farmakol/predn/cz/2009/Hypolipidemika%202009.ppt >.
[10] Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP (1993). "Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study". J Clin Pharmacol 33 (3): 226–9. doi:10.1002/j.1552-4604.1993.tb03948.x. PMID 8463436.
[11] Marcoff L, Thompson PD (2007). "The role of coenzyme Q10 in statin-associated myopathy: a systematic review". J. Am. Coll. Cardiol. 49 (23): 2231–7. doi:10.1016/j.jacc.2007.02.049. PMID 17560286.
[12] Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008). "SLCO1B1 Variants and Statin-Induced Myopathy – A Genomewide Study". NEJM 359 (8): 789–799. doi:10.1056/NEJMoa0801936. PMID 18650507.
[13] Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH (2007). "The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity". J. Clin. Invest. 117 (12): 3940–51. doi:10.1172/JCI32741. PMC 2066198. PMID 17992259.
[14] Statiny, od lipidologie ke kardiologii, Michal Vrablík, Richard Češka, Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha, Klin Farmakol Farm 2005; 19: 149–151 www.klinickafarmakologie.cz/pdfs/far/2005/03/04.pdf
[15] Ateroskleroza a nove pohledy, Doc. MUDr. Kunešová a kol. Grada, ISBN 978-80-247-3052-3, str. 147
[16] www.tribune.cz/clanek/28190-poruchy-metabolismu-lipidu-a-terapie-statiny-ve-stari
[17] www.prolekare.cz/kreditovane-kurzy/moznosti-nefarmakologickeho-ovlivneni-hypercholesterolemie-101/moznosti-nefarmakologickeho-ovlivneni-hypercholesterolemie-95
[18] pacbio.com/biomarker/assay-detail/333/
[19] www.ncbi.nlm.nih.gov/pmc/articles/PMC4033986/
[20] www.hindawi.com/journals/ije/2015/934681/
[21] academic.oup.com/eurheartj/article/34/suppl_1/P614/2859951
[22] article.sapub.org/10.5923.j.ajb.20170703.03.html
[23] www.medista.cz/lp-pla2-469/
[24] www.ncbi.nlm.nih.gov/pmc/articles/PMC4107429/
[25] www.imalab.cz/clanek/187-apoe-polymorfizmus-e2-e3-e4.aspx
[26] www2.ikem.cz/plm_lp/_LP_18049.htm
[27] en.wikipedia.org/wiki/Apolipoprotein_E
[28] www.alzdiscovery.org/cognitive-vitality/blog/what-apoe-means-for-your-health
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
:::: ====
